{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:09:07Z","timestamp":1740107347601,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00415-024-12650-4","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T15:02:06Z","timestamp":1725030126000},"page":"6847-6855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sparse item testing of clinical scales in neurology trials to alleviate burden to patients"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9791-4727","authenticated-orcid":false,"given":"Chao","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Novakovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris","family":"Jamsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Vong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usman","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"12650_CR1","unstructured":"Disability-adjusted life years (DALYs). Available from: https:\/\/www.who.int\/data\/gho\/indicator-metadata-registry\/imr-details\/158. Accessed 23 Aug 2024"},{"issue":"10","key":"12650_CR2","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/S2468-2667(20)30190-0","volume":"5","author":"G Deuschl","year":"2020","unstructured":"Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E et al (2020) The burden of neurological diseases in Europe: an analysis for the global burden of disease study 2017. Lancet Public Heal 5(10):e551\u2013e567","journal-title":"Lancet Public Heal"},{"issue":"5","key":"12650_CR3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s13311-022-01292-x","volume":"19","author":"LB Reoma","year":"2022","unstructured":"Reoma LB, Karp BI (2022) The human cost: patient contribution to clinical trials in neurology. Neurotherapeutics 19(5):1503\u20131506","journal-title":"Neurotherapeutics"},{"issue":"2","key":"12650_CR4","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S et al (2022) Two randomized phase 3 studies of aducanumab in early alzheimer\u2019s disease. J Prev Alzheimer\u2019s Dis 9(2):197\u2013210","journal-title":"J Prev Alzheimer\u2019s Dis"},{"issue":"1","key":"12650_CR5","first-page":"142","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early alzheimer\u2019s disease. N Engl J Med [Online] 388(1):142\u2013143","journal-title":"N Engl J Med [Online]"},{"issue":"6","key":"12650_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J et al (2023) Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527","journal-title":"JAMA"},{"issue":"8","key":"12650_CR7","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jval.2011.06.003","volume":"14","author":"S Rolstad","year":"2011","unstructured":"Rolstad S, Adler J, Ryd\u00e9n A (2011) Response burden and questionnaire length: is shorter better? A review and meta-analysis. Value Health 14(8):1101\u20131108","journal-title":"Value Health"},{"issue":"1","key":"12650_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-33826-4","volume":"13","author":"OL Aiyegbusi","year":"2022","unstructured":"Aiyegbusi OL, Roydhouse J, Rivera SC, Kamudoni P, Schache P, Wilson R et al (2022) Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection. Nat Commun 13(1):1\u20138","journal-title":"Nat Commun"},{"issue":"4","key":"12650_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/psp4.12280","volume":"7","author":"S Ueckert","year":"2018","unstructured":"Ueckert S (2018) Modeling composite assessment data using item response theory. CPT Pharmacometrics Syst Pharmacol 7(4):205\u2013218","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"12650_CR10","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s11095-017-2216-1","volume":"34","author":"S Buatois","year":"2017","unstructured":"Buatois S, Retout S, Frey N, Ueckert S (2017) Item response theory as an efficient tool to describe a heterogeneous clinical rating scale in de novo idiopathic parkinson\u2019s disease patients. Pharm Res 34(10):2109\u20132118","journal-title":"Pharm Res"},{"issue":"3","key":"12650_CR11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1208\/s12248-017-0058-8","volume":"19","author":"G Gottipati","year":"2017","unstructured":"Gottipati G, Karlsson MO, Plan EL (2017) Modeling a composite score in parkinson\u2019s disease using item response theory. AAPS J 19(3):837\u2013845","journal-title":"AAPS J"},{"issue":"6","key":"12650_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/psp4.12632","volume":"10","author":"D Chae","year":"2021","unstructured":"Chae D, Chung SJ, Lee PH, Park K (2021) Predicting the longitudinal changes of levodopa dose requirements in Parkinson\u2019s disease using item response theory assessment of real-world unified parkinson\u2019s disease rating scale. CPT Pharmacometrics Syst Pharmacol 10(6):611\u2013621","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"12650_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/psp4.12601","volume":"10","author":"C Chen","year":"2021","unstructured":"Chen C, J\u00f6nsson S, Yang S, Plan EL, Karlsson MO (2021) Detecting placebo and drug effects on Parkinson\u2019s disease symptoms by longitudinal item-score models. CPT Pharmacometrics Syst Pharmacol 10(4):309\u2013317","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"12650_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mdc3.13311","volume":"8","author":"S Luo","year":"2021","unstructured":"Luo S, Zou H, Goetz CG, Choi D, Oakes D, Simuni T et al (2021) Novel approach to movement disorder society-unified parkinson\u2019s disease rating scale monitoring in clinical trials: longitudinal item response theory models. Mov Disord Clin Pract 8(7):1083\u20131091","journal-title":"Mov Disord Clin Pract"},{"issue":"9","key":"12650_CR15","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1111\/bcp.14777","volume":"87","author":"Y Sheng","year":"2021","unstructured":"Sheng Y, Zhou X, Yang S, Ma P, Chen C (2021) Modelling item scores of Unified Parkinson\u2019s disease rating scale part III for greater trial efficiency. Br J Clin Pharmacol 87(9):3608\u20133618","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"12650_CR16","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/psp4.12853","volume":"11","author":"H Zou","year":"2022","unstructured":"Zou H, Aggarwal V, Stebbins GT, M\u00fcller MLTM, Cedarbaum JM, Pedata A et al (2022) Application of longitudinal item response theory models to modeling Parkinson\u2019s disease progression. CPT Pharmacometrics Syst Pharmacol 11(10):1382\u20131392","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"12650_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jalz.2011.05.2409","volume":"8","author":"S Balsis","year":"2012","unstructured":"Balsis S, Unger AA, Benge JF, Geraci L, Doody RS (2012) Gaining precision on the Alzheimer\u2019s disease assessment scale-cognitive: a comparison of item response theory-based scores and total scores. Alzheimers Dement 8(4):288\u2013294","journal-title":"Alzheimers Dement"},{"issue":"8","key":"12650_CR18","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1007\/s11095-014-1315-5","volume":"31","author":"S Ueckert","year":"2014","unstructured":"Ueckert S, Plan EL, Ito K, Karlsson MO, Corrigan B, Hooker AC (2014) Improved utilization of ADAS-Cog assessment data through item response theory based pharmacometric modeling. Pharm Res 31(8):2152\u20132165","journal-title":"Pharm Res"},{"issue":"5","key":"12650_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000335727","volume":"32","author":"TM Miller","year":"2011","unstructured":"Miller TM, Balsis S, Lowe DA, Benge JF, Doody RS (2011) Item response theory reveals variability of functional impairment within clinical dementia rating scale stages. Dement Geriatr Cogn Disord 32(5):362\u2013366","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"11","key":"12650_CR20","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1111\/bcp.13715","volume":"84","author":"J Guk","year":"2018","unstructured":"Guk J, Chae D, Son H, Yoo J, Heo JH, Park K (2018) Model-based assessment of the benefits and risks of recombinant tissue plasminogen activator treatment in acute ischaemic stroke. Br J Clin Pharmacol 84(11):2586\u20132599","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"12650_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/psp4.12207","volume":"6","author":"EHJ Krekels","year":"2017","unstructured":"Krekels EHJ, Novakovic AM, Vermeulen AM, Friberg LE, Karlsson MO (2017) Item response theory to quantify longitudinal placebo and paliperidone effects on PANSS scores in schizophrenia. CPT Pharmacometrics Syst Pharmacol 6(8):543\u2013551","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"12650_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s10802-013-9756-6","volume":"41","author":"TM Olino","year":"2013","unstructured":"Olino TM, Yu L, McMakin DL, Forbes EE, Seeley JR, Lewinsohn PM et al (2013) Comparisons across depression assessment instruments in adolescence and young adulthood: an item response theory study using two linking methods. J Abnorm Child Psychol 41(8):1267\u20131277","journal-title":"J Abnorm Child Psychol"},{"issue":"10","key":"12650_CR23","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/psp4.13018","volume":"12","author":"ME Otto","year":"2023","unstructured":"Otto ME, Bergmann KR, de Kam ML, Recourt K, Jacobs GE, van Esdonk MJ (2023) Item response theory in early phase clinical trials: utilization of a reference model to analyze the montgomery-\u00e5sberg depression rating scale. CPT pharmacometrics Syst Pharmacol 12(10):1425\u20131436","journal-title":"CPT pharmacometrics Syst Pharmacol"},{"issue":"5","key":"12650_CR24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s10928-018-9602-0","volume":"45","author":"D Chae","year":"2018","unstructured":"Chae D, Park K (2018) An item response theory based integrated model of headache, nausea, photophobia, and phonophobia in migraine patients. J Pharmacokinet Pharmacodyn 45(5):721\u2013731","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"12","key":"12650_CR25","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1002\/psp4.13048","volume":"12","author":"PW Chen","year":"2023","unstructured":"Chen PW, Karlsson MO, Ueckert S, Pritchard-Bell A, Hsu CP, Dutta S et al (2023) Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine. CPT Pharmacometrics Syst Pharmacol 12(12):1988\u20132000","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"12650_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1208\/s12248-016-9977-z","volume":"19","author":"AM Novakovic","year":"2017","unstructured":"Novakovic AM, Krekels EHJ, Munafo A, Ueckert S, Karlsson MO (2017) Application of item response theory to modeling of expanded disability status scale in multiple sclerosis. AAPS J 19(1):172\u2013179","journal-title":"AAPS J"},{"issue":"5","key":"12650_CR27","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/mds.10248","volume":"17","author":"C Ramaker","year":"2002","unstructured":"Ramaker C, Marinus J, Stiggelbout AM, van Hilten BJ (2002) Systematic evaluation of rating scales for impairment and disability in Parkinson\u2019s disease. Mov Disord 17(5):867\u2013876","journal-title":"Mov Disord"},{"issue":"7","key":"12650_CR28","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"Disease MDSTF on RS for P","year":"2003","unstructured":"Disease MDSTF on RS for P (2003) The unified Parkinson\u2019s disease rating scale (UPDRS): status and recommendations. Mov Disord 18(7):738\u2013750","journal-title":"Mov Disord"},{"issue":"6","key":"12650_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Breteler MM (2006) Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5(6):525\u2013535","journal-title":"Lancet Neurol"},{"issue":"8","key":"12650_CR30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm 124(8):901\u2013905","journal-title":"J Neural Transm"},{"issue":"14","key":"12650_CR31","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","volume":"68","author":"R Pahwa","year":"2007","unstructured":"Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP et al (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68(14):1108\u20131115","journal-title":"Neurology"},{"issue":"2","key":"12650_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1208\/s12248-012-9327-8","volume":"14","author":"C Vong","year":"2012","unstructured":"Vong C, Bergstrand M, Nyberg J, Karlsson MO (2012) Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models. AAPS J 14(2):176\u2013186","journal-title":"AAPS J"},{"issue":"1","key":"12650_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2012.24","volume":"2","author":"KE Karlsson","year":"2013","unstructured":"Karlsson KE, Vong C, Bergstrand M, Jonsson EN, Karlsson MO (2013) Comparisons of analysis methods for proof-of-concept trials. CPT Pharmacometrics Syst Pharmacol 2(1):1\u20138","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"12650_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/psp4.12404","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ (2019) NONMEM tutorial Part I: description of commands and options, with simple examples of population analysis. CPT Pharmacometrics Syst Pharmacol 8(8):525","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"12650_CR35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/psp4.12422","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ (2019) NONMEM tutorial part II: estimation methods and advanced examples. CPT pharmacometrics Syst Pharmacol 8(8):538\u2013556","journal-title":"CPT pharmacometrics Syst Pharmacol"},{"issue":"2","key":"12650_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75(2):85\u201394","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"12650_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson N (2005) PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3):241\u2013257","journal-title":"Comput Methods Programs Biomed"},{"key":"12650_CR38","unstructured":"Population Pharmacokinetics Guidance for Industry. 2022. Available from: https:\/\/www.fda.gov\/media\/128793\/download. Accessed 23 Aug 2024"},{"issue":"15","key":"12650_CR39","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement disorder society-sponsored revision of the unified parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170","journal-title":"Mov Disord"},{"issue":"2","key":"12650_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/jnnp.71.2.220","volume":"71","author":"C Jenkinson","year":"2001","unstructured":"Jenkinson C, Fitzpatrick R, Garratt A, Peto V, Stewart-Brown S (2001) Can item response theory reduce patient burden when measuring health status in neurological disorders? Results from rasch analysis of the SF-36 physical functioning scale (PF-10). J Neurol Neurosurg Psychiatry 71(2):220\u2013224","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"12650_CR41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10928-020-09697-x","volume":"47","author":"L Arrington","year":"2020","unstructured":"Arrington L, Ueckert S, Ahamadi M, Macha S, Karlsson MO (2020) Performance of longitudinal item response theory models in shortened or partial assessments. J Pharmacokinet Pharmacodyn 47(5):461\u2013471","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"12650_CR42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11136-011-9958-8","volume":"21","author":"RC Gershon","year":"2012","unstructured":"Gershon RC, Lai JS, Bode R, Choi S, Moy C, Bleck T et al (2012) Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res 21(3):475\u2013486","journal-title":"Qual Life Res"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12650-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T03:54:42Z","timestamp":1727927682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12650-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["12650"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12650-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors conducted this research as employees of their respective affiliations. The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}